Payload Information
General Information of This Payload
| Payload ID | PAY0WUZLC |
|||||
|---|---|---|---|---|---|---|
| Name | Camptothecin |
|||||
| Synonyms |
Camptothecin; 7689-03-4; Camptothecine; (S)-(+)-Camptothecin; Campathecin; (+)-Camptothecine; d-Camptothecin; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; Camptothecine (S,+); CHEMBL65; (S)-4-ethyl-4-hydroxy-1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NSC-94600; MLS000766223; XT3Z54Z28A; CHEBI:27656; MFCD00081076; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione; (S)-Camptothecin; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 20(S)-Camptothecin; 4-ETHYL-4-HYDROXY-1,12-DIHYDRO-4H-2-OXA-6,12A-DIAZA-DIBENZO[B,H]FLUORENE-3,13-DIONE; SR-01000075798; SR-01000597379; d-camptothecine; (s)-camptothecine; Camptothecin,(S); (4S)-4-ETHYL-4-HYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE; (S)-4-ethyl-4-hydroxy-1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; Prestwick_102; (+)-Camptothecin;; Camptothecine (8CI); Spectrum_000299; Tocris-1100; SpecPlus_000712; Prestwick0_000200; Prestwick1_000200; Prestwick2_000200; Prestwick3_000200; Spectrum2_000903; Spectrum3_001203; Spectrum4_000738; Spectrum5_001126; CAMPTOTHECIN [MI]; Lopac-C-9911; D09YDM; SCHEMBL6038; UNII-XT3Z54Z28A; Lopac0_000341; BSPBio_000159; BSPBio_002586; KBioGR_001036; KBioSS_000779; KBioSS_002283; cid_24360; CAMPTOTHECIN [WHO-DD]; DivK1c_000826; DivK1c_006808; SPECTRUM1502232; SPBio_000746; SPBio_002080; BPBio1_000175; DTXSID0030956; HMS502J08; KBio1_000826; KBio1_001752; KBio2_000779; KBio2_003347; KBio2_005915; KBio3_002086; 4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NINDS_000826; Bio1_000400; Bio1_000889; Bio1_001378; HMS1568H21; HMS1921N08; HMS2089F08; HMS2095H21; HMS3261E03; HMS3414J17; HMS3654D13; HMS3678J15; HMS3712H21; BCP02857; Tox21_500341; AC-202; BBL033963; BDBM50008923; CCG-40255; GR-301; s1288; STK801886; AKOS004119861; CS-1049; DB04690; KS-5235; LP00341; SDCCGMLS-0066688.P001; SDCCGSBI-0050329.P003; CAS-2114454; IDI1_000826; NCGC00015290-01; NCGC00016994-01; NCGC00016994-02; NCGC00016994-03; NCGC00016994-04; NCGC00016994-05; NCGC00016994-06; NCGC00016994-07; NCGC00016994-08; NCGC00016994-09; NCGC00016994-10; NCGC00016994-11; NCGC00016994-12; NCGC00016994-16; NCGC00016994-29; NCGC00024997-01; NCGC00024997-02; NCGC00024997-03; NCGC00024997-04; NCGC00024997-05; NCGC00024997-06; NCGC00178592-01; NCGC00178592-02; NCGC00261026-01; HY-16560; NCI60_042105; SMR000445686; SY010324; EU-0100341; SW196414-3; C 9911; C01897; M01564; AB00052452-08; AB00052452-09; AB00052452_10; EN300-1725804; (S)-(+)-Camptothecin, >=90% (HPLC), powder; A838882; Q419964; Q-200785; SR-01000075798-1; SR-01000075798-4; SR-01000597379-1; SR-01000597379-3; BRD-K37890730-001-09-4; BRD-K37890730-001-10-2; Z1741982070; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]florene-3,13-dione; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 4-Ethyl-4-hydroxy-1H-pyrano-[3[,4[:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(S)-(+)-Camptothecin; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 4(S)-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H)-dione; 4-ethyl-4-hydroxy-(4S)-3,4,12,14-tetrahydro-1H-pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-3,14-dione; 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (camptothecin or CPT); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (Camptothecin); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (CPT, Camptothecin)
Click to Show/Hide
|
|||||
| Target | DNA topoisomerase 1 (TOP1) | |||||
| Structure |
|
|||||
| Formula | C20H16N2O4 |
|||||
| Isosmiles | CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
|
|||||
| InChIKey |
VSJKWCGYPAHWDS-FQEVSTJZSA-N
|
|||||
| IUPAC Name |
(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
|
|||||
| Pharmaceutical Properties | Molecule Weight |
348.4 |
Polar area |
79.7 |
||
Complexity |
742 |
xlogp Value |
1 |
|||
Heavy Count |
26 |
Rot Bonds |
1 |
|||
Hbond acc |
5 |
Hbond Donor |
1 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) | 0.001 | ug/mL |
Lu-99 cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.00463 | ug/mL |
QG-56 cells
|
Lung squamous cell carcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.00463 | ug/mL |
QG-56 cells
|
Lung squamous cell carcinoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.00474 | ug/mL |
P388 cells
|
Lymphoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.00474 | ug/mL |
P388 cells
|
Lymphoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.005 | ug/mL |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | <0.005 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[3] | |
| Half Maximal Inhibitory Concentration (IC50) | <0.005 | ug/mL |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[3] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.005 | ug/mL |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
SW480 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.0147 | ug/mL |
HOC-21 cells
|
Ovarian adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.0147 | ug/mL |
HOC-21 cells
|
Ovarian adenocarcinoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug/mL |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug/mL |
Vero cells
|
Normal
|
[5] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug/mL |
HEp-2 cells
|
Laryngeal carcinoma
|
[6] | |
| Half Maximal Inhibitory Concentration (IC50) | <0.024 | ug/mL |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[7] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.03 | ug/mL |
KB VCR R cells
|
Normal
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.03 | ug/mL |
WI-38 cells
|
Normal
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.04 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.054 | ug/mL |
Vero cells
|
Normal
|
[9] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.054 | ug/mL |
Vero cells
|
Normal
|
[10] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.07 | ug/mL |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.07 | ug/mL |
WiDr cells
|
Colon adenocarcinoma
|
[6] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.072 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[12] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.09 | ug/mL |
Hep-G2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.096 | ug/mL |
HCT 15 cells
|
Colon adenocarcinoma
|
[12] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.19 | ug/mL |
HeLa cells
|
Endocervical adenocarcinoma
|
[6] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.28 | ug/mL |
HeLa cells
|
Endocervical adenocarcinoma
|
[13] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | ug/mL |
WI-38 cells
|
Normal
|
[14] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | ug/mL |
Vero cells
|
Normal
|
[15] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.54 | ug/mL |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[12] | |
| Half Maximal Inhibitory Concentration (IC50) | 11.71 | ug/mL |
L-M(TK-) cells
|
Normal
|
[16] | |
| Half Maximal Inhibitory Concentration (IC50) | <2 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[17] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | ug/mL |
CCD 19Lu cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.05 | ug/mL |
RPMI-8226 cells
|
Plasma cell myeloma
|
[16] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.72 | ug/mL |
Bel-7402 cells
|
Hepatoma
|
[3] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.87 | ug/mL |
Embryonic fibroblast MEF cells
|
Normal
|
Undisclosed | [16] |
| Half Maximal Inhibitory Concentration (IC50) | 58 | ug/mL |
Vero cells
|
Normal
|
[13] | |
| Half Maximal Inhibitory Concentration (IC50) | 6.88 | ug/mL |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
[12] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 0.023 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[18] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.02543 | nM |
ES7 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.04 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.04843 | nM |
NCI-H209 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.09574 | nM |
ES1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1016 | nM |
P12-Ichikawa cells
|
T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1214 | nM |
EW-16 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1293 | nM |
MHH-ES-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1315 | nM |
D-566MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1398 | nM |
BFTC-905 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.15 | nM |
HCT 116 cells
|
Colon carcinoma
|
[20] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.1714 | nM |
639-V cells
|
Ureter urothelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1816 | nM |
HSC-4 cells
|
Cervical lymph node
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1936 | nM |
NBsusSR cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.2119 | nM |
HT-3 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.2738 | nM |
NTERA-2-cl-D1 cells
|
Teratocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.3192 | nM |
EW-3 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | nM |
LN-229 cells
|
Glioblastoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | nM |
LoVo cells
|
Colon adenocarcinoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | nM |
MHCC97H cells
|
Hepatocellular carcinoma
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.3582 | nM |
H9 cells
|
Sezary syndrome
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4281 | nM |
COLO-800 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4292 | nM |
CTB-1 cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.441 | nM |
NKM-1 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4809 | nM |
Daoy cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[22] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.513 | nM |
MC-IXC cells
|
Askin tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5292 | nM |
NCI-H1048 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5392 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5566 | nM |
EW-22 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.56 | nM |
HEK293 cells
|
Normal
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.5694 | nM |
NB69 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5865 | nM |
LU-134-A cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[20] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.6022 | nM |
DoHH2 CDX model cells
|
Diffuse large B-cell lymphoma germinal center B-cell type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.6143 | nM |
NB10 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.6154 | nM |
H4 cells
|
Neuroglioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[24] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.701 | nM |
GR-ST cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7058 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7058 | nM |
GOTO cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7318 | nM |
MOLT-16 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7479 | nM |
NCI-H1623 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7735 | nM |
ES5 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7753 | nM |
QIMR-WIL cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7956 | nM |
ES8 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8149 | nM |
A673 cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8157 | nM |
DEL/BVR cells
|
Anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8385 | nM |
HO-1-N-1 cells
|
Buccal mucosa squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.84 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[25] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.8418 | nM |
MHH-NB-11 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8814 | nM |
HuP-T4 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8868 | nM |
OCI-AML-2 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8964 | nM |
647-V cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.9022 | nM |
RS4
11 cells |
Adult B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.9054 | nM |
CTV-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.9071 | nM |
NB14 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.9311 | nM |
ES3 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.981 | nM |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.9836 | nM |
CAL-62 cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[26] | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
NCI-H69 cells
|
Small cell lung carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.026 | nM |
CHP-212 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.028 | nM |
NCI-H526 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.11 | nM |
KG-1 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.16 | nM |
SK-PN-DW cells
|
Primitive neuroectodermal tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.161 | nM |
DB cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.188 | nM |
NCI-H1155 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.227 | nM |
SK-NEP-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.241 | nM |
SAS cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.398 | nM |
HOS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.399 | nM |
HN cells
|
Cervical lymph node
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.4 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.4 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.474 | nM |
ES4 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.502 | nM |
8-MG-BA cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.527 | nM |
GAMG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.534 | nM |
ALL-PO cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.535 | nM |
KE-37 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.557 | nM |
NOMO-1 cells
|
Acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[34] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[35] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.614 | nM |
T24 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.616 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.634 | nM |
HD-MY-Z cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.669 | nM |
A3-KAW cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.699 | nM |
NCI-H510A cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.725 | nM |
RPMI-8866 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.749 | nM |
A4-Fuk cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.759 | nM |
GT3TKB cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.777 | nM |
EW-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.787 | nM |
MOLT-13 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | <1.8 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[36] | |
| Half Maximal Inhibitory Concentration (IC50) | <1.8 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[36] | |
| Half Maximal Inhibitory Concentration (IC50) | <1.8 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[36] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.814 | nM |
HCE-4 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.822 | nM |
BHT-101 cells
|
Anaplastic thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.853 | nM |
BB65-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.869 | nM |
U-251MG cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.869 | nM |
L-363 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.925 | nM |
NB5 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[37] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
ZR-75-1 cells
|
Invasive breast carcinoma
|
[38] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
U-251MG cells
|
Astrocytoma
|
[40] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[41] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[42] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[43] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[44] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[45] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[46] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[47] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[49] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[50] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[51] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[52] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[54] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[55] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[56] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[57] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
BT-20 cells
|
Invasive breast carcinoma of no special type
|
[38] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
HCT 116 cells
|
Colon carcinoma
|
[38] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
Hep 3B2.1-7 cells
|
Childhood hepatocellular carcinoma
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[38] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | <10 | nM |
SF539 cells
|
Gliosarcoma
|
[61] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[42] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[45] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[49] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[50] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[52] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[54] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[55] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[56] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[57] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF539 cells
|
Gliosarcoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[38] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF268 cells
|
Astrocytoma
|
[46] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
SF268 cells
|
Astrocytoma
|
[47] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[37] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[41] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[41] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[60] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[52] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[62] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[63] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[57] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
Panel NCI-60 cells
|
Normal
|
Undisclosed | [64] |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
Hs 683 cells
|
Glioma
|
[37] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
DMS-273 cells
|
Small cell lung carcinoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | <10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[61] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[42] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[43] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[44] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[45] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[46] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[47] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[49] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[50] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[51] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[52] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[54] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[55] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[57] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[59] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | <10 | nM |
UACC-62 cells
|
Melanoma
|
[61] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[42] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[43] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[44] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[45] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[46] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[47] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[65] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[49] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[50] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[52] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[54] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[55] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[56] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[57] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10 | nM |
UACC-62 cells
|
Melanoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | <10 | nM |
MCF-12A cells
|
Normal
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
PC-3 cells
|
Prostate carcinoma
|
[37] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
DU145 cells
|
Prostate carcinoma
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
SK-MES-1 cells
|
Lung squamous cell carcinoma
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
Human umbilical vein endothelial cells(HUVEC)
|
Normal
|
Undisclosed | [70] |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
HEK293 cells
|
Normal
|
[71] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
GLC4 cells
|
Lung small cell carcinoma
|
[72] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
P388 cells
|
Lymphoma
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 10.12 | nM |
A388 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.51 | nM |
Ramos-2G6-4C10 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.56 | nM |
IST-MES1 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.59 | nM |
KGN cells
|
Ovarian granulosa cell tumor
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 10.64 | nM |
UACC-62 cells
|
Melanoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 10.78 | nM |
SK-MES-1 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
HCT 116 cells
|
Colon carcinoma
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
HCT 116 cells
|
Colon carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
Mahlavu cells
|
Hepatoma
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | <100 | nM |
FOCUS cells
|
Hepatocellular carcinoma
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[78] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
PC-3 cells
|
Prostate carcinoma
|
[80] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
DU145 cells
|
Prostate carcinoma
|
[80] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[81] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
CNE-2 cells
|
Normal
|
[82] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[83] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
HCT 116 cells
|
Colon carcinoma
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
Hep 3B2.1-7 cells
|
Childhood hepatocellular carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
Mahlavu cells
|
Hepatoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
SNU-475 cells
|
Hepatocellular carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
MFE-296 cells
|
Endometrial adenocarcinoma
|
[67] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1000 | nM |
CEM/C2 cells
|
T acute lymphoblastic leukemia
|
[84] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
FOCUS cells
|
Hepatocellular carcinoma
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
FOCUS cells
|
Hepatocellular carcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM |
QSG-7701 cells
|
Endocervical adenocarcinoma
|
[83] | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
Raji cells
|
EBV-related Burkitt lymphoma
|
[86] | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
DU145 cells
|
Prostate carcinoma
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
HCT 116 cells
|
Colon carcinoma
|
[88] | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | >1000 | nM |
CEM/C2 cells
|
T acute lymphoblastic leukemia
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[89] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
MIA PaCa-2 cells (MSLN expression)
|
Pancreatic ductal adenocarcinoma
|
[90] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[91] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
Peripheral blood mononuclear cells
|
Normal
|
Undisclosed | [90] |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
[92] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
P388 cells
|
Lymphoma
|
[93] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
P388 cells
|
Lymphoma
|
[94] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
P388 cells
|
Lymphoma
|
[95] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
P388CPT45 cells
|
Lymphoma
|
[96] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
P388CPT45 cells
|
Lymphoma
|
[97] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CPT-K5 cells
|
T acute lymphoblastic leukemia
|
[96] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CPT-K5 cells
|
T acute lymphoblastic leukemia
|
[93] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CPT-K5 cells
|
T acute lymphoblastic leukemia
|
[94] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CPT-K5 cells
|
T acute lymphoblastic leukemia
|
[97] | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
SH-SY5Y cells
|
Bone marrow neuroblastoma
|
[98] | |
| Half Maximal Inhibitory Concentration (IC50) | 10070 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[99] | |
| Half Maximal Inhibitory Concentration (IC50) | 1009.34 | nM |
NCI-H727 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1010 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[100] | |
| Half Maximal Inhibitory Concentration (IC50) | 1010 | nM |
HEK293 cells
|
Normal
|
[101] | |
| Half Maximal Inhibitory Concentration (IC50) | 10100 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[102] | |
| Half Maximal Inhibitory Concentration (IC50) | 102.32 | nM |
WM-115 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 102.97 | nM |
KP-N-YN cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1030 | nM |
BT-483 cells
|
Ductal carcinoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 1040 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[104] | |
| Half Maximal Inhibitory Concentration (IC50) | 105.42 | nM |
NCI-H358 cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 106.62 | nM |
SK-N-FI cells
|
Neuroblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 106.66 | nM |
NCI-H322M cells
|
Minimally invasive lung adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 1060 | nM |
DU145 cells
|
Prostate carcinoma
|
[101] | |
| Half Maximal Inhibitory Concentration (IC50) | 1060 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[105] | |
| Half Maximal Inhibitory Concentration (IC50) | 1060 | nM |
HFL1 cells
|
Normal
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 107.08 | nM |
BEN cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1070 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 1077.74 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 108.94 | nM |
BALL-1 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1080 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[88] | |
| Half Maximal Inhibitory Concentration (IC50) | 1080 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[107] | |
| Half Maximal Inhibitory Concentration (IC50) | 1080 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
[108] | |
| Half Maximal Inhibitory Concentration (IC50) | 109.27 | nM |
COLO-741 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 109.97 | nM |
TGBC1TKB cells
|
Gallbladder undifferentiated carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1093.19 | nM |
HT-1197 cells
|
Recurrent bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
A-431 cells
|
Skin squamous cell carcinoma
|
[109] | |
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
ADR5000 cells
|
Leukemia
|
[110] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 11.07 | nM |
U-251MG cells
|
Astrocytoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 11.26 | nM |
KMOE-2 cells
|
Erythroleukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 11.35 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 11.5 | nM |
HCT 116 cells
|
Colon carcinoma
|
[111] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 11.51 | nM |
SF268 cells
|
Astrocytoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 11.53 | nM |
SF-295 cells
|
Glioblastoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 11.56 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 11.64 | nM |
ACHN cells
|
Renal adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 11.65 | nM |
YH-13 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.67 | nM |
COLO-829 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.7 | nM |
HSC-2 cells
|
Oral cavity squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 11.8 | nM |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 11.97 | nM |
NCI-ADR-RES cells
|
High grade ovarian serous adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM |
DU145 cells
|
Prostate carcinoma
|
[112] | |
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM |
DU145 cells
|
Prostate carcinoma
|
[113] | |
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM |
DU145 cells
|
Prostate carcinoma
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM |
HCT 116 cells
|
Colon carcinoma
|
[114] | |
| Half Maximal Inhibitory Concentration (IC50) | 110 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[115] | |
| Half Maximal Inhibitory Concentration (IC50) | 110.1 | nM |
NCI-H1395 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1100 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[116] | |
| Half Maximal Inhibitory Concentration (IC50) | 11120 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[117] | |
| Half Maximal Inhibitory Concentration (IC50) | 11170 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[118] | |
| Half Maximal Inhibitory Concentration (IC50) | 113.08 | nM |
no-11 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 113.62 | nM |
RCC10RGB cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11360 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[119] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 114.82 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 115.84 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 115.96 | nM |
UACC-257 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 116.78 | nM |
BxPC-3 CDX model cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11620 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[120] | |
| Half Maximal Inhibitory Concentration (IC50) | 117.2 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[121] | |
| Half Maximal Inhibitory Concentration (IC50) | 1170 | nM |
KATO III cells
|
Down syndrome
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1180 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[100] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 12 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[122] | |
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
IA-LM cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
PC-3 cells
|
Prostate carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
Human umbilical vein endothelial cells(HUVEC)
|
Normal
|
Undisclosed | [123] |
| Half Maximal Inhibitory Concentration (IC50) | 12.24 | nM |
TGBC11TKB cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.49 | nM |
GP5d cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.65 | nM |
HuO-3N1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.76 | nM |
A-172 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.86 | nM |
HCC38 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.98 | nM |
NCI-H2122 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 120 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[98] | |
| Half Maximal Inhibitory Concentration (IC50) | 120 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[124] | |
| Half Maximal Inhibitory Concentration (IC50) | 120 | nM |
HCT 116 cells
|
Colon carcinoma
|
[125] | |
| Half Maximal Inhibitory Concentration (IC50) | 120 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[126] | |
| Half Maximal Inhibitory Concentration (IC50) | 120 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 120 | nM |
LX-1 cells
|
Lung carcinoma
|
[127] | |
| Half Maximal Inhibitory Concentration (IC50) | 120.28 | nM |
BB49-HNC cells
|
Floor of mouth squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1200 | nM |
PC-3 cells
|
Prostate carcinoma
|
[128] | |
| Half Maximal Inhibitory Concentration (IC50) | 1200 | nM |
PC-3 cells
|
Prostate carcinoma
|
[129] | |
| Half Maximal Inhibitory Concentration (IC50) | 1200 | nM |
NCI-H1975 cells
|
Lung adenocarcinoma
|
[130] | |
| Half Maximal Inhibitory Concentration (IC50) | 12000 | nM |
NIH3T3 cells
|
Normal
|
[131] | |
| Half Maximal Inhibitory Concentration (IC50) | 121 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[132] | |
| Half Maximal Inhibitory Concentration (IC50) | 121.91 | nM |
CAS-1 cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 122.18 | nM |
HOP-18 cells
|
Non-small cell lung adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 1220 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[133] | |
| Half Maximal Inhibitory Concentration (IC50) | 1220 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[133] | |
| Half Maximal Inhibitory Concentration (IC50) | 1220 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[133] | |
| Half Maximal Inhibitory Concentration (IC50) | 1220 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[133] | |
| Half Maximal Inhibitory Concentration (IC50) | 124.47 | nM |
LAN-6 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1240 | nM |
RD cells
|
Rhabdomyosarcoma
|
[134] | |
| Half Maximal Inhibitory Concentration (IC50) | 1240 | nM |
RD cells
|
Rhabdomyosarcoma
|
[135] | |
| Half Maximal Inhibitory Concentration (IC50) | 12500 | nM |
Bel-7402 cells
|
Hepatoma
|
[136] | |
| Half Maximal Inhibitory Concentration (IC50) | 12500 | nM |
Bel-7402 cells
|
Hepatoma
|
[137] | |
| Half Maximal Inhibitory Concentration (IC50) | 126 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 126.89 | nM |
EFM-19 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1270 | nM |
BGC-823 cells
|
Stomach adenocarcinoma
|
[138] | |
| Half Maximal Inhibitory Concentration (IC50) | 127000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[139] | |
| Half Maximal Inhibitory Concentration (IC50) | 12750 | nM |
BT474-M1 cells
|
Invasive breast carcinoma
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | 128.79 | nM |
SNU-423 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1290 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[118] | |
| Half Maximal Inhibitory Concentration (IC50) | <13 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[140] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 13 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[54] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 13 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[55] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 13 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[56] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 13 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[61] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 13 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | <13 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[140] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[88] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
A375 cells
|
Amelanotic melanoma
|
[141] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
P388 cells
|
Lymphoma
|
[142] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
P388 cells
|
Lymphoma
|
[143] | |
| Half Maximal Inhibitory Concentration (IC50) | 13.12 | nM |
JEG-3 cells
|
Gestational choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.18 | nM |
KYSE-180 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.34 | nM |
Detroit 562 cells
|
Pharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.37 | nM |
C32 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.52 | nM |
T-47D cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.52 | nM |
HH cells
|
T-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.54 | nM |
U2OS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.55 | nM |
NCI-H661 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.58 | nM |
PC-14 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.71 | nM |
NCI-H2170 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.82 | nM |
COLO-684 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[144] | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[24] | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[145] | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM |
HCT 116 cells
|
Colon carcinoma
|
[146] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1300 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[147] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1300 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[148] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1300 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[149] | |
| Half Maximal Inhibitory Concentration (IC50) | 1300 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[22] | |
| Half Maximal Inhibitory Concentration (IC50) | 1300 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[150] | |
| Half Maximal Inhibitory Concentration (IC50) | 130000 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[151] | |
| Half Maximal Inhibitory Concentration (IC50) | 1310 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[152] | |
| Half Maximal Inhibitory Concentration (IC50) | 13200 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[82] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1324.34 | nM |
TK-10 cells
|
Renal carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 134.42 | nM |
MDA-MB-415 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 134.47 | nM |
KARPAS-45 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1360 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[108] | |
| Half Maximal Inhibitory Concentration (IC50) | 13620 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[153] | |
| Half Maximal Inhibitory Concentration (IC50) | 13640 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[102] | |
| Half Maximal Inhibitory Concentration (IC50) | 1367.35 | nM |
HCC1395 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1370 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[154] | |
| Half Maximal Inhibitory Concentration (IC50) | 1370 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[155] | |
| Half Maximal Inhibitory Concentration (IC50) | 1370 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[156] | |
| Half Maximal Inhibitory Concentration (IC50) | 13700 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 1380 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[101] | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[157] | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[158] | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[159] | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[160] | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
Bel-7402 cells
|
Hepatoma
|
[161] | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
P388 cells
|
Lymphoma
|
[162] | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
P388 cells
|
Lymphoma
|
[96] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 14.03 | nM |
SN12C cells
|
Renal cell carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 14.09 | nM |
A-549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.11 | nM |
MZ2-MEL cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 14.49 | nM |
SF539 cells
|
Gliosarcoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 14.54 | nM |
JAR cells
|
Gestational choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.55 | nM |
TI-73 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.75 | nM |
CFPAC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.88 | nM |
RT-112 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.91 | nM |
RO82-W-1 cells
|
Thyroid gland follicular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.93 | nM |
LoVo cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.95 | nM |
Capan-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.95 | nM |
NCI-H1651 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 14.96 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 140 | nM |
A-172 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 140 | nM |
BEL-7404 tumor cells
|
Endocervical adenocarcinoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 140 | nM |
L02 cells
|
Cervical carcinoma
|
[163] | |
| Half Maximal Inhibitory Concentration (IC50) | 1400 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[164] | |
| Half Maximal Inhibitory Concentration (IC50) | 14000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[165] | |
| Half Maximal Inhibitory Concentration (IC50) | 14000000 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
[166] | |
| Half Maximal Inhibitory Concentration (IC50) | 1410 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[138] | |
| Half Maximal Inhibitory Concentration (IC50) | 1414.4 | nM |
PC-3 cells
|
Prostate carcinoma
|
[121] | |
| Half Maximal Inhibitory Concentration (IC50) | 14200 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[116] | |
| Half Maximal Inhibitory Concentration (IC50) | 144.23 | nM |
MKN7 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144.69 | nM |
Hs 578T cells
|
Invasive breast carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 145.21 | nM |
MDA-N cells
|
Breast carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 1460 | nM |
DU145 cells
|
Prostate carcinoma
|
[167] | |
| Half Maximal Inhibitory Concentration (IC50) | 147.61 | nM |
TE-10 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14760 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
[168] | |
| Half Maximal Inhibitory Concentration (IC50) | 148.3 | nM |
L-428 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 149.39 | nM |
NCI-H1650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
DU145 cells
|
Prostate carcinoma
|
[169] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[170] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
786-O cells
|
Renal cell carcinoma
|
[171] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[172] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
[93] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
[95] | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
U-373MG ATCC cells
|
Astrocytoma
|
[37] | |
| Half Maximal Inhibitory Concentration (IC50) | 15.35 | nM |
A704 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.74 | nM |
RD cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.75 | nM |
DSH1 cells
|
Bladder carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 15.78 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 15.8 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[132] | |
| Half Maximal Inhibitory Concentration (IC50) | 15.86 | nM |
MC116 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 150 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | 150.08 | nM |
EW-18 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 150.28 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 150.37 | nM |
NCI-H1563 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 150.57 | nM |
CAL-72 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[173] | |
| Half Maximal Inhibitory Concentration (IC50) | >150000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | >150000 | nM |
HGC-27 cells
|
Gastric carcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | >150000 | nM |
MGC-803 cells
|
Gastric cancer
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | >150000 | nM |
L02 cells
|
Cervical carcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | >150000 | nM |
HCCLM9 cells
|
Adult hepatocellular carcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | 151.26 | nM |
IGR-1 cells
|
Cutaneous melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 151.71 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 1520 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[138] | |
| Half Maximal Inhibitory Concentration (IC50) | 15200 | nM |
FHCC-98 cells
|
Hepatocellular carcinoma
|
[175] | |
| Half Maximal Inhibitory Concentration (IC50) | 1530 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[101] | |
| Half Maximal Inhibitory Concentration (IC50) | 1540 | nM |
LoVo cells
|
Colon adenocarcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 1543.63 | nM |
SHP-77 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1552.36 | nM |
A-431 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1560 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 157.32 | nM |
NCI-H1770 cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1570 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[176] | |
| Half Maximal Inhibitory Concentration (IC50) | 1570 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[177] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 158.85 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 159 | nM |
HCT 116 cells
|
Colon carcinoma
|
[178] | |
| Half Maximal Inhibitory Concentration (IC50) | 159 | nM |
HCT 116 cells
|
Colon carcinoma
|
[179] | |
| Half Maximal Inhibitory Concentration (IC50) | 1590 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[180] | |
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[181] | |
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
DU145 cells
|
Prostate carcinoma
|
[182] | |
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
HCT 116 cells
|
Colon carcinoma
|
[183] | |
| Half Maximal Inhibitory Concentration (IC50) | 16.13 | nM |
AGS cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.33 | nM |
TE-11 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.44 | nM |
LU-139 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.8 | nM |
NB7 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 160 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[115] | |
| Half Maximal Inhibitory Concentration (IC50) | 1600 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[165] | |
| Half Maximal Inhibitory Concentration (IC50) | 1600 | nM |
KG-1 cells
|
Adult acute myeloid leukemia
|
[184] | |
| Half Maximal Inhibitory Concentration (IC50) | 162 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 162.01 | nM |
NCI-H520 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1620 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[180] | |
| Half Maximal Inhibitory Concentration (IC50) | 16240 | nM |
PC-3 cells
|
Prostate carcinoma
|
[185] | |
| Half Maximal Inhibitory Concentration (IC50) | 16440 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[186] | |
| Half Maximal Inhibitory Concentration (IC50) | 165 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
[159] | |
| Half Maximal Inhibitory Concentration (IC50) | 166 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[187] | |
| Half Maximal Inhibitory Concentration (IC50) | 166 | nM |
HGC-27 cells
|
Gastric carcinoma
|
[156] | |
| Half Maximal Inhibitory Concentration (IC50) | 1660 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[188] | |
| Half Maximal Inhibitory Concentration (IC50) | 1670 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 168.37 | nM |
AsPC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 169.17 | nM |
COLO-792 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[109] | |
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
MKN45 cells
|
Gastric adenocarcinoma
|
[157] | |
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
HCT 116 cells
|
Colon carcinoma
|
[189] | |
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
WiDr cells
|
Colon adenocarcinoma
|
[157] | |
| Half Maximal Inhibitory Concentration (IC50) | 17.13 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.34 | nM |
SNB-75 cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 17.38 | nM |
HCT 116 cells
|
Colon carcinoma
|
[56] | |
| Half Maximal Inhibitory Concentration (IC50) | 17.64 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.73 | nM |
D-392MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.77 | nM |
SAOS-2 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.86 | nM |
HT-144 cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 17.95 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 170 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[190] | |
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[189] | |
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
MDA-MB-361 cells
|
Breast adenocarcinoma
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[191] | |
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
4T1 cells
|
Mammary carcinoma
|
[77] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1700 | nM |
WiDr cells
|
Colon adenocarcinoma
|
[147] | |
| Half Maximal Inhibitory Concentration (IC50) | 1700 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[184] | |
| Half Maximal Inhibitory Concentration (IC50) | 1700 | nM |
MRC5 cells
|
Normal
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 1700 | nM |
MX1 cells
|
Breast carcinoma
|
[192] | |
| Half Maximal Inhibitory Concentration (IC50) | 1710 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
[193] | |
| Half Maximal Inhibitory Concentration (IC50) | 1720 | nM |
RD cells
|
Rhabdomyosarcoma
|
[152] | |
| Half Maximal Inhibitory Concentration (IC50) | 173.4 | nM |
NCI-H1573 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 173.78 | nM |
Malme-3M cells
|
Melanoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 174.04 | nM |
no-10 cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 176.6 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 178.42 | nM |
NCI-H2126 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 178.5 | nM |
TE-6 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 178.95 | nM |
Calu-6 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1780.55 | nM |
HT-1376 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
SJSA-1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[194] | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[195] | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[196] | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[197] | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[198] | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
NCI-H128 cells
|
Lung carcinoma
|
[157] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 18.11 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 18.13 | nM |
HEC-1 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 18.16 | nM |
SNB-19 cells
|
Astrocytoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 18.2 | nM |
DU145 cells
|
Prostate carcinoma
|
[56] | |
| Half Maximal Inhibitory Concentration (IC50) | 18.37 | nM |
LB831-BLC cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.57 | nM |
SCC-15 cells
|
Squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.71 | nM |
NCI-H1666 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.92 | nM |
DOK cells
|
Oral epithelial dysplasia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 180 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[199] | |
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
PANC-1 cells
|
Pancreatic ductal adenocarcinoma
|
[200] | |
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[201] | |
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[202] | |
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[171] | |
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
MIA PaCa-2 cells (MSLN expression)
|
Pancreatic ductal adenocarcinoma
|
[203] | |
| Half Maximal Inhibitory Concentration (IC50) | 180.87 | nM |
SK-LMS-1 cells
|
Vulvar leiomyosarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1800 | nM |
WiDr cells
|
Colon adenocarcinoma
|
[204] | |
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[205] | |
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM |
Ca-Ski cells
|
Cervical squamous cell carcinoma
|
[206] | |
| Half Maximal Inhibitory Concentration (IC50) | 182.71 | nM |
NB6 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18240 | nM |
PC-3 cells
|
Prostate carcinoma
|
[186] | |
| Half Maximal Inhibitory Concentration (IC50) | 18300 | nM |
QSG-7701 cells
|
Endocervical adenocarcinoma
|
[175] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 184.08 | nM |
IGROV-1 cells
|
Ovarian endometrioid adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 184.93 | nM |
COR-L105 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1840 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[201] | |
| Half Maximal Inhibitory Concentration (IC50) | 1840 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[202] | |
| Half Maximal Inhibitory Concentration (IC50) | 1840 | nM |
MS cells
|
Diffuse large B-cell lymphoma
|
[134] | |
| Half Maximal Inhibitory Concentration (IC50) | 185.61 | nM |
NCI-H2347 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | <1850 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | <1850 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | <1850 | nM |
HCT 116 cells
|
Colon carcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | <1850 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | <1850 | nM |
RKO cells
|
Colon carcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | <1850 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | <1850 | nM |
C6 cells
|
Glioma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | <1850 | nM |
SGC-7901 cells
|
Gastric carcinoma
|
[174] | |
| Half Maximal Inhibitory Concentration (IC50) | 1850 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[167] | |
| Half Maximal Inhibitory Concentration (IC50) | 188.55 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1880 | nM |
HCT 116 cells
|
Colon carcinoma
|
[135] | |
| Half Maximal Inhibitory Concentration (IC50) | 1880 | nM |
HCT 116 cells
|
Colon carcinoma
|
[152] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 19 | nM |
DU145 cells
|
Prostate carcinoma
|
[207] | |
| Half Maximal Inhibitory Concentration (IC50) | 19 | nM |
U-118-MG cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[178] | |
| Half Maximal Inhibitory Concentration (IC50) | 19 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[179] | |
| Half Maximal Inhibitory Concentration (IC50) | 19.16 | nM |
G-401 cells
|
Kidney Wilm's tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.16 | nM |
CAL-39 cells
|
Vulvar squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.26 | nM |
SCC-4 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.37 | nM |
LS-513 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 19.41 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 19.42 | nM |
KNS-81-FD cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.46 | nM |
23132-87 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.68 | nM |
Panc1005 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.82 | nM |
NMC-G1 cells
|
Astrocytoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 190 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[40] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 190 | nM |
SF268 cells
|
Astrocytoma
|
[208] | |
| Half Maximal Inhibitory Concentration (IC50) | 190 | nM |
MIA PaCa-2 cells (MSLN expression)
|
Pancreatic ductal adenocarcinoma
|
[128] | |
| Half Maximal Inhibitory Concentration (IC50) | 190 | nM |
MIA PaCa-2 cells (MSLN expression)
|
Pancreatic ductal adenocarcinoma
|
[129] | |
| Half Maximal Inhibitory Concentration (IC50) | 190 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[209] | |
| Half Maximal Inhibitory Concentration (IC50) | 190 | nM |
SF268 cells
|
Astrocytoma
|
[117] | |
| Half Maximal Inhibitory Concentration (IC50) | 190 | nM |
PC-3M cells
|
Bone metastasis of prostate carcinoma
|
[210] | |
| Half Maximal Inhibitory Concentration (IC50) | 190.35 | nM |
SW1116 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1900 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[147] | |
| Half Maximal Inhibitory Concentration (IC50) | 192.44 | nM |
HT55 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 194.29 | nM |
SNU-449 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 195 | nM |
HCT 116 cells
|
Colon carcinoma
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 196.84 | nM |
LB771-HNC cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1980 | nM |
U-937 cells
|
Adult acute monocytic leukemia
|
[211] | |
| Half Maximal Inhibitory Concentration (IC50) | 1980 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[212] | |
| Half Maximal Inhibitory Concentration (IC50) | 19800 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[213] | |
| Half Maximal Inhibitory Concentration (IC50) | 1985.76 | nM |
BT474-M1 cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
[214] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[41] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[84] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[207] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[215] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[216] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[86] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[217] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[182] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
HCT 116 cells
|
Colon carcinoma
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[218] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.01 | nM |
HCT 116 cells
|
Colon carcinoma
|
[219] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.018 | nM |
CAL-27 cells
|
Tongue adenosquamous carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.029 | nM |
697 cells
|
Childhood B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.043 | nM |
ATN-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.076 | nM |
LB2241-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.082 | nM |
BPH-1 cells
|
Benign prostatic hyperplasia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2.1 | nM |
MSTO-211H cells
|
Pleural biphasic mesothelioma
|
[215] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.165 | nM |
ML-2 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.175 | nM |
NB17 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.21 | nM |
IMR-32 cells
|
Neuroblastoma
|
[220] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.21 | nM |
VM-CUB-1 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.211 | nM |
Ca9-22 cells
|
Gingival squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.217 | nM |
RPMI-2650 cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.24 | nM |
NCI-H292 cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.3 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[182] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.348 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.381 | nM |
BV-173 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.406 | nM |
ONS-76 cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.438 | nM |
C2BBe1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.504 | nM |
JVM-3 cells
|
B-cell prolymphocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.506 | nM |
OC-314 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.551 | nM |
D-423MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.551 | nM |
HAL-01 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.579 | nM |
J-RT3-T3-5 cells
|
T acute lymphoblastic leukemi
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.659 | nM |
EW-11 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.692 | nM |
ME-180 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.733 | nM |
MHH-PREB-1 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.759 | nM |
MIA PaCa-2 cells (MSLN expression)
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.774 | nM |
MS-1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.792 | nM |
P30-OHK cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.806 | nM |
LC-2-ad cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.835 | nM |
SF-126 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.881 | nM |
HuO9 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.902 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.993 | nM |
SW13 cells
|
Adrenal cortex carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[42] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[43] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[44] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[46] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[47] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[65] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[49] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[50] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[51] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[52] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[54] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[57] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[61] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20 | nM |
SN12C cells
|
Renal cell carcinoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[157] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[169] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
DU145 cells
|
Prostate carcinoma
|
[222] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
DU145 cells
|
Prostate carcinoma
|
[201] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
DU145 cells
|
Prostate carcinoma
|
[202] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
HCT 116 cells
|
Colon carcinoma
|
[223] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[145] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[24] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[157] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[140] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
[185] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
MDA-MB-157 cells
|
Breast carcinoma
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
[73] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20.18 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 20.32 | nM |
EFO-21 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.33 | nM |
MZ1-PC cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.35 | nM |
SW 954 cells
|
Vulva squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.49 | nM |
LCLC-103H cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.51 | nM |
SW 962 cells
|
Vulva lymphoid carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20.56 | nM |
DMS 114 cells
|
Lung small cell carcinoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 20.65 | nM |
M14 cells
|
Melanoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 200 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[148] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[128] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[129] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[224] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
SW1990 cells
|
Pancreatic adenocarcinoma
|
[225] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Human umbilical vein endothelial cells(HUVEC)
|
Normal
|
Undisclosed | [144] |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2000 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[149] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2000 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[204] | |
| Half Maximal Inhibitory Concentration (IC50) | 2000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[91] | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
[214] | |
| Half Maximal Inhibitory Concentration (IC50) | >200000 | nM |
NCI-H446 cells
|
Lung small cell carcinoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | >200000 | nM |
NCI-H446 cells
|
Lung small cell carcinoma
|
[223] | |
| Half Maximal Inhibitory Concentration (IC50) | 207 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[226] | |
| Half Maximal Inhibitory Concentration (IC50) | 208.15 | nM |
CP66-MEL cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 208.78 | nM |
NCI-H1755 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 209.41 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 21 | nM |
DU145 cells
|
Prostate carcinoma
|
[227] | |
| Half Maximal Inhibitory Concentration (IC50) | 21 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[123] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 21.38 | nM |
786-O cells
|
Renal cell carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 21.55 | nM |
BB30-HNC cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.56 | nM |
MFE-280 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.69 | nM |
SK-N-DZ cells
|
Neuroblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 210 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[227] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 210 | nM |
DU145 cells
|
Prostate carcinoma
|
[122] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 210 | nM |
DU145 cells
|
Prostate carcinoma
|
[228] | |
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 210 | nM |
SW1573 cells
|
Lung carcinoma
|
[147] | |
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[105] | |
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
DU145 cells
|
Prostate carcinoma
|
[229] | |
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
Capan-1 cells
|
Pancreatic ductal adenocarcinoma
|
[200] | |
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
SW480 cells
|
Colon adenocarcinoma
|
[197] | |
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
BGC-823 cells
|
Stomach adenocarcinoma
|
[230] | |
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
HPDE6c7 cells
|
Normal
|
[203] | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[231] | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[232] | |
| Half Maximal Inhibitory Concentration (IC50) | 2110 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[171] | |
| Half Maximal Inhibitory Concentration (IC50) | 2150 | nM |
L02 cells
|
Cervical carcinoma
|
[233] | |
| Half Maximal Inhibitory Concentration (IC50) | 218.07 | nM |
GAK cells
|
Vulvar melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2190 | nM |
MCF-10A cells
|
Normal
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 22.03 | nM |
KU-19-19 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.32 | nM |
COLO-668 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 22.34 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 22.49 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 22.54 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 22.59 | nM |
D-502MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.87 | nM |
RERF-LC-MS cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[42] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[43] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[45] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[46] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[49] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[50] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[52] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[54] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[55] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[56] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[57] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[61] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[59] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
SK-HEP1 cells
|
Hepatoma
|
[199] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 220 | nM |
SK-HEP1 cells
|
Hepatoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 220 | nM |
SK-HEP1 cells
|
Hepatoma
|
[171] | |
| Half Maximal Inhibitory Concentration (IC50) | 220 | nM |
RPMI-7951 cells
|
Malignant melanoma
|
[234] | |
| Half Maximal Inhibitory Concentration (IC50) | 22000 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[235] | |
| Half Maximal Inhibitory Concentration (IC50) | 2210 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[186] | |
| Half Maximal Inhibitory Concentration (IC50) | 2260 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
[236] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 227.51 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 2281.94 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2281.97 | nM |
SK-MEL-30 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 229.98 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[237] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 23.01 | nM |
HCT 116 cells
|
Colon carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 23.34 | nM |
Becker cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.65 | nM |
TE-9 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.73 | nM |
KYSE-450 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 230 | nM |
HBL-100 cells
|
Normal
|
[147] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 230 | nM |
HBL-100 cells
|
Normal
|
[204] | |
| Half Maximal Inhibitory Concentration (IC50) | 230 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[229] | |
| Half Maximal Inhibitory Concentration (IC50) | 230 | nM |
WI-38 cells
|
Normal
|
[238] | |
| Half Maximal Inhibitory Concentration (IC50) | 230 | nM |
MS cells
|
Diffuse large B-cell lymphoma
|
[239] | |
| Half Maximal Inhibitory Concentration (IC50) | 2300 | nM |
HCT 116 cells
|
Colon carcinoma
|
[116] | |
| Half Maximal Inhibitory Concentration (IC50) | 2310 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[240] | |
| Half Maximal Inhibitory Concentration (IC50) | 2320 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
[105] | |
| Half Maximal Inhibitory Concentration (IC50) | 2370 | nM |
DU145 cells
|
Prostate carcinoma
|
[100] | |
| Half Maximal Inhibitory Concentration (IC50) | 23760 | nM |
AGS cells
|
Gastric adenocarcinoma
|
[171] | |
| Half Maximal Inhibitory Concentration (IC50) | 23980 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[241] | |
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[242] | |
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
A-427 cells
|
Lung carcinoma
|
[243] | |
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[161] | |
| Half Maximal Inhibitory Concentration (IC50) | 24.12 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24.16 | nM |
SW872 cells
|
Liposarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 24.49 | nM |
SN12K1 cells
|
Lung metastasis of renal carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 24.5 | nM |
G-402 cells
|
Kidney neoplasm
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24.57 | nM |
SW1783 cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 240 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[244] | |
| Half Maximal Inhibitory Concentration (IC50) | 240 | nM |
BxPC-3 CDX model cells
|
Pancreatic ductal adenocarcinoma
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 240 | nM |
ZR-75-30 cells
|
Breast carcinoma
|
[125] | |
| Half Maximal Inhibitory Concentration (IC50) | 241 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[189] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 242.66 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 2430 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[245] | |
| Half Maximal Inhibitory Concentration (IC50) | 244.5 | nM |
RMG-I cells
|
Ovarian clear cell adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 245.96 | nM |
KYSE-150 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24770 | nM |
MCF10 cells
|
Normal
|
Undisclosed | [246] |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
Sf9 cells
|
Normal
|
[247] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
Sf9 cells
|
Normal
|
[248] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
KB-V1 cells
|
Cervical carcinoma
|
[93] | |
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
KB-V1 cells
|
Cervical carcinoma
|
[95] | |
| Half Maximal Inhibitory Concentration (IC50) | 25.07 | nM |
EGI-1 cells
|
Cholangiocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.34 | nM |
769-P cells
|
Renal cell carcinom
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 25.35 | nM |
P388/ADR cells
|
Lymphoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 25.55 | nM |
OE33 cells
|
Barrett adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 25.64 | nM |
RXF 393 cells
|
Renal carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 25.78 | nM |
SW780 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.99 | nM |
BT-20 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 250 | nM |
SW1573 cells
|
Lung carcinoma
|
[204] | |
| Half Maximal Inhibitory Concentration (IC50) | 250 | nM |
HCT 116 cells
|
Colon carcinoma
|
[249] | |
| Half Maximal Inhibitory Concentration (IC50) | 250 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[241] | |
| Half Maximal Inhibitory Concentration (IC50) | 2500 | nM |
PC-3 cells
|
Prostate carcinoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 2500 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[247] | |
| Half Maximal Inhibitory Concentration (IC50) | 2500 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[248] | |
| Half Maximal Inhibitory Concentration (IC50) | 2500 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[248] | |
| Half Maximal Inhibitory Concentration (IC50) | >25000 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[250] | |
| Half Maximal Inhibitory Concentration (IC50) | >25000 | nM |
GLC-82 cells
|
Endocervical adenocarcinoma
|
[250] | |
| Half Maximal Inhibitory Concentration (IC50) | 2511.11 | nM |
UMC-11 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 253.14 | nM |
NCI-H1838 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2530 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[164] | |
| Half Maximal Inhibitory Concentration (IC50) | 2544 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[187] | |
| Half Maximal Inhibitory Concentration (IC50) | 2544.45 | nM |
G-361 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 256.33 | nM |
SNU-387 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 257.84 | nM |
A101D cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2580 | nM |
MCF-10A cells
|
Normal
|
[105] | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[211] | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
KBH5.0 cells
|
Endocervical adenocarcinoma
|
[93] | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
KBH5.0 cells
|
Endocervical adenocarcinoma
|
[95] | |
| Half Maximal Inhibitory Concentration (IC50) | 26.03 | nM |
PFSK-1 cells
|
Primitive neuroectodermal tumor
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 26.06 | nM |
LOX IMVI cells
|
Melanoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 26.67 | nM |
P388 cells
|
Lymphoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 26.69 | nM |
NCI-H1693 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[251] | |
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[125] | |
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[251] | |
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[100] | |
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[112] | |
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[232] | |
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[251] | |
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
Bel-7402 cells
|
Hepatoma
|
[251] | |
| Half Maximal Inhibitory Concentration (IC50) | 260.2 | nM |
SW948 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2600 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[205] | |
| Half Maximal Inhibitory Concentration (IC50) | 261 | nM |
ZR-75-30 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2610 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[114] | |
| Half Maximal Inhibitory Concentration (IC50) | 262.05 | nM |
CAL-12T cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2620 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[240] | |
| Half Maximal Inhibitory Concentration (IC50) | 264 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 26450 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[120] | |
| Half Maximal Inhibitory Concentration (IC50) | 265.25 | nM |
TE-12 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 266.61 | nM |
HCC1954 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 267.54 | nM |
HCC1569 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 269.5 | nM |
COLO-824 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.08 | nM |
MFH-ino cells
|
Pleomorphic sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.15 | nM |
T98G cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 27.16 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 27.16 | nM |
SNB-75 cells
|
Glioblastoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 27.23 | nM |
NCI-H1793 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.24 | nM |
MPP-89 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.5 | nM |
MKN45 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.77 | nM |
SW1088 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.79 | nM |
SBC-1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 270 | nM |
MCF-10A cells
|
Normal
|
[99] | |
| Half Maximal Inhibitory Concentration (IC50) | 2700 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[223] | |
| Half Maximal Inhibitory Concentration (IC50) | 2700 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[205] | |
| Half Maximal Inhibitory Concentration (IC50) | 27000 | nM |
Vero cells
|
Normal
|
[131] | |
| Half Maximal Inhibitory Concentration (IC50) | 27200 | nM |
TERT-RPE1 cells
|
Normal
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 276.33 | nM |
Lu-65 cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2770 | nM |
HCT 116 cells
|
Colon carcinoma
|
[167] | |
| Half Maximal Inhibitory Concentration (IC50) | 2780 | nM |
B16-F10 cells
|
Mouse melanoma
|
[252] | |
| Half Maximal Inhibitory Concentration (IC50) | 28.16 | nM |
LU-135 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.34 | nM |
NCI-H2052 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.4 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[253] | |
| Half Maximal Inhibitory Concentration (IC50) | 28.66 | nM |
RCM-1 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.7 | nM |
DU145 cells
|
Prostate carcinoma
|
[132] | |
| Half Maximal Inhibitory Concentration (IC50) | 28.7 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[254] | |
| Half Maximal Inhibitory Concentration (IC50) | 28.7 | nM |
Lu1 cells
|
Lung carcinoma
|
Undisclosed | [254] |
| Half Maximal Inhibitory Concentration (IC50) | 28.7 | nM |
SW626 cells
|
Colon adenocarcinoma
|
[254] | |
| Half Maximal Inhibitory Concentration (IC50) | 28.8 | nM |
NB13 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 280 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[136] | |
| Half Maximal Inhibitory Concentration (IC50) | 280 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[230] | |
| Half Maximal Inhibitory Concentration (IC50) | 280 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[255] | |
| Half Maximal Inhibitory Concentration (IC50) | 280 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[99] | |
| Half Maximal Inhibitory Concentration (IC50) | 280 | nM |
HEK293 cells
|
Normal
|
[212] | |
| Half Maximal Inhibitory Concentration (IC50) | 280 | nM |
SNU-638 cells
|
Gastric carcinoma
|
[256] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2800 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 2800 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[223] | |
| Half Maximal Inhibitory Concentration (IC50) | 282.32 | nM |
NCI-H630 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2820 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[201] | |
| Half Maximal Inhibitory Concentration (IC50) | 2820 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[202] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 285.76 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 28660 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[102] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | >287000 | nM |
PC-3 cells
|
Prostate carcinoma
|
[190] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | >287000 | nM |
U2OS cells
|
Osteosarcoma
|
[190] | |
| Half Maximal Inhibitory Concentration (IC50) | 2892.53 | nM |
Karpas-299 cells/Karpas BVR cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[161] | |
| Half Maximal Inhibitory Concentration (IC50) | 29.49 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.6 | nM |
YAPC cells
|
Pancreas carincoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.71 | nM |
HT cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.74 | nM |
CAL-51 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 290 | nM |
SW480 cells
|
Colon adenocarcinoma
|
[257] | |
| Half Maximal Inhibitory Concentration (IC50) | 2900000 | nM |
Caov-3 cells
|
Ovarian serous adenocarcinoma
|
[166] | |
| Half Maximal Inhibitory Concentration (IC50) | 291 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[158] | |
| Half Maximal Inhibitory Concentration (IC50) | 291.41 | nM |
D-542MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 296.49 | nM |
NCI-H747 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2960 | nM |
MGC-803 cells
|
Gastric cancer
|
[258] | |
| Half Maximal Inhibitory Concentration (IC50) | 2968.73 | nM |
NCI-H596 cells
|
Lung adenosquamous carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 297.85 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 298.06 | nM |
SJRH30 cells
|
Alveolar rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29810 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[98] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 3 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[207] | |
| Half Maximal Inhibitory Concentration (IC50) | <3 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | <3 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[223] | |
| Half Maximal Inhibitory Concentration (IC50) | <3 | nM |
MV3 cells
|
Amelanotic melanoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[110] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
HCT 116 cells
|
Colon carcinoma
|
[141] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[259] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[22] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
[260] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.015 | nM |
HSC-3 cells
|
Oral squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.017 | nM |
SW48 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.041 | nM |
BCPAP cells
|
Thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.067 | nM |
SK-UT-1 cells
|
Uterine corpus leiomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.067 | nM |
DU-4475 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.069 | nM |
PSN1 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.093 | nM |
UM-UC-3 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.1 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[243] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.108 | nM |
NEC8 cells
|
Testicular embryonal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.136 | nM |
NUGC-3 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.143 | nM |
HCC1806 cells
|
Breast squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.162 | nM |
KP-4 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.198 | nM |
D283 Med cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.267 | nM |
EW-13 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.275 | nM |
CGTH-W-1 cells
|
Thyroid gland squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.3 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[24] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.301 | nM |
8505C cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.344 | nM |
HC-1 cells
|
Hairy cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.365 | nM |
GI-1 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.379 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.382 | nM |
HuTu 80 cells
|
Duodenal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.468 | nM |
ABC-1 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.469 | nM |
VA-ES-BJ cells
|
Epithelioid sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.599 | nM |
A2058 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.68 | nM |
AU565 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.688 | nM |
A375 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.72 | nM |
LOX IMVI cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.734 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.793 | nM |
NH-12 cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.81 | nM |
IST-MEL1 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.853 | nM |
ECC10 cells
|
Gastric small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.854 | nM |
LU-99A cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.86 | nM |
RH-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
Caov-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
Caov-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[42] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[43] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[46] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[47] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[49] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[50] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[52] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[54] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[55] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[56] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[57] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[59] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[208] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[222] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[261] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
PC-3 cells
|
Prostate carcinoma
|
[222] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
HCT 116 cells
|
Colon carcinoma
|
[261] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[198] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[261] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[104] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[117] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[261] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[262] | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
WI-38 cells
|
Normal
|
[263] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 30.27 | nM |
UO-31 cells
|
Renal carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
U-937 cells
|
Adult acute monocytic leukemia
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[91] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[137] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[264] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[113] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[265] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[78] | |
| Half Maximal Inhibitory Concentration (IC50) | >300 | nM |
H69AR cells
|
Lung small cell carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
ADR5000 cells
|
Leukemia
|
[90] | |
| Half Maximal Inhibitory Concentration (IC50) | 3010 | nM |
HEp-2 cells
|
Laryngeal carcinoma
|
[152] | |
| Half Maximal Inhibitory Concentration (IC50) | 3029.5 | nM |
JVM-2 cells
|
Mantle cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 304 | nM |
Renca cells
|
Renal carcinoma
|
[198] | |
| Half Maximal Inhibitory Concentration (IC50) | 304.67 | nM |
ChaGo-K-1 cells
|
Bronchogenic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3040 | nM |
HEp-2 cells
|
Laryngeal carcinoma
|
[134] | |
| Half Maximal Inhibitory Concentration (IC50) | 3040 | nM |
HEp-2 cells
|
Laryngeal carcinoma
|
[135] | |
| Half Maximal Inhibitory Concentration (IC50) | 307 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[266] | |
| Half Maximal Inhibitory Concentration (IC50) | 307 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[267] | |
| Half Maximal Inhibitory Concentration (IC50) | 3090 | nM |
T24 cells
|
Bladder carcinoma
|
[233] | |
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 31.03 | nM |
LNCaP-Clone-FGC cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.03 | nM |
UACC-62 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.47 | nM |
HTC-C3 cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.84 | nM |
SW900 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.85 | nM |
DMS-79 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 310 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[228] | |
| Half Maximal Inhibitory Concentration (IC50) | 310 | nM |
DU145 cells
|
Prostate carcinoma
|
[107] | |
| Half Maximal Inhibitory Concentration (IC50) | 310 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 310 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 310 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[268] | |
| Half Maximal Inhibitory Concentration (IC50) | 3100 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[137] | |
| Half Maximal Inhibitory Concentration (IC50) | 3100 | nM |
LoVo cells
|
Colon adenocarcinoma
|
[269] | |
| Half Maximal Inhibitory Concentration (IC50) | 311.44 | nM |
NCI-H69 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3120 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[136] | |
| Half Maximal Inhibitory Concentration (IC50) | 314.07 | nM |
HCC1187 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3140 | nM |
NCI-H1299 cells (MMAE resistant)
|
Lung large cell carcinoma
|
[171] | |
| Half Maximal Inhibitory Concentration (IC50) | 3150 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[136] | |
| Half Maximal Inhibitory Concentration (IC50) | 31860 | nM |
MDA-MB-436 cells
|
Metastasis of ductal carcinoma
|
[241] | |
| Half Maximal Inhibitory Concentration (IC50) | 32 | nM |
U-937 cells
|
Adult acute monocytic leukemia
|
[270] | |
| Half Maximal Inhibitory Concentration (IC50) | 32 | nM |
P388 cells
|
Lymphoma
|
[271] | |
| Half Maximal Inhibitory Concentration (IC50) | 32.1 | nM |
P388 cells
|
Lymphoma
|
[272] | |
| Half Maximal Inhibitory Concentration (IC50) | 32.15 | nM |
SBC-5 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32.8 | nM |
Calu-3 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 320 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 320 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[273] | |
| Half Maximal Inhibitory Concentration (IC50) | 3200 | nM |
DU145 cells
|
Prostate carcinoma
|
[88] | |
| Half Maximal Inhibitory Concentration (IC50) | 3200 | nM |
DU145 cells
|
Prostate carcinoma
|
[116] | |
| Half Maximal Inhibitory Concentration (IC50) | 3200 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[137] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 3210 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[228] | |
| Half Maximal Inhibitory Concentration (IC50) | 32110 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[235] | |
| Half Maximal Inhibitory Concentration (IC50) | 32300 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[274] | |
| Half Maximal Inhibitory Concentration (IC50) | 3270 | nM |
Raji cells
|
EBV-related Burkitt lymphoma
|
[186] | |
| Half Maximal Inhibitory Concentration (IC50) | 3273.33 | nM |
OE19 cells
|
Esophageal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 329.41 | nM |
SK-MEL3 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3293.6 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 33 | nM |
U-373MG ATCC cells
|
Astrocytoma
|
[148] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
Lewis lung carcinoma cells
|
Lung carcinoma
|
[275] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
Lewis lung carcinoma cells
|
Lung carcinoma
|
[142] | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
Lewis lung carcinoma cells
|
Lung carcinoma
|
[143] | |
| Half Maximal Inhibitory Concentration (IC50) | 33.14 | nM |
KNS-42 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.19 | nM |
SCC-9 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.5 | nM |
NCI-H1581 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.57 | nM |
SW1710 cells
|
Bladder carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 33.65 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 33.73 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 33.89 | nM |
GI-ME-N cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.98 | nM |
AN3-CA cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 330 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[276] | |
| Half Maximal Inhibitory Concentration (IC50) | 330 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[185] | |
| Half Maximal Inhibitory Concentration (IC50) | 330 | nM |
Carcinoma cells
|
Carcinoma
|
Undisclosed | [277] |
| Half Maximal Inhibitory Concentration (IC50) | 330 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[278] | |
| Half Maximal Inhibitory Concentration (IC50) | 330000 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[166] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 332.66 | nM |
SNB-78 cells
|
Glioblastoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 332.9 | nM |
KINGS-1 cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3320 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[279] | |
| Half Maximal Inhibitory Concentration (IC50) | 334.48 | nM |
NCI-H1975 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34 | nM |
CT26 cells
|
Colon carcinoma
|
[198] | |
| Half Maximal Inhibitory Concentration (IC50) | 34.07 | nM |
UO-31 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34.38 | nM |
IST-SL1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34.43 | nM |
MDA-MB-361 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34.89 | nM |
ETK-1 cells
|
Cholangiocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34.93 | nM |
NCI-H1437 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 340 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 340 | nM |
CNE cells
|
Nasopharyngeal carcinoma
|
[108] | |
| Half Maximal Inhibitory Concentration (IC50) | 342 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[280] | |
| Half Maximal Inhibitory Concentration (IC50) | 349.21 | nM |
HCC1937 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[141] | |
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[104] | |
| Half Maximal Inhibitory Concentration (IC50) | 35.11 | nM |
TF-1 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.38 | nM |
SNU-C2B cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.45 | nM |
CW-2 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 35.48 | nM |
HCT 116 cells
|
Colon carcinoma
|
[56] | |
| Half Maximal Inhibitory Concentration (IC50) | 35.53 | nM |
LK-2 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.62 | nM |
MEL-JUSO cells
|
Cutaneous melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 350 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[228] | |
| Half Maximal Inhibitory Concentration (IC50) | 350 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[209] | |
| Half Maximal Inhibitory Concentration (IC50) | 350 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[281] | |
| Half Maximal Inhibitory Concentration (IC50) | 350 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[163] | |
| Half Maximal Inhibitory Concentration (IC50) | 3500 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[92] | |
| Half Maximal Inhibitory Concentration (IC50) | 3570 | nM |
DU145 cells
|
Prostate carcinoma
|
[282] | |
| Half Maximal Inhibitory Concentration (IC50) | 36.34 | nM |
IGROV-1 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36.35 | nM |
HuP-T3 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 36.64 | nM |
SW620 cells
|
Colon adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 3600 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[224] | |
| Half Maximal Inhibitory Concentration (IC50) | 3600 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[26] | |
| Half Maximal Inhibitory Concentration (IC50) | 3634.01 | nM |
KURAMOCHI cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3670 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[193] | |
| Half Maximal Inhibitory Concentration (IC50) | 3682.73 | nM |
COLO-678 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[283] | |
| Half Maximal Inhibitory Concentration (IC50) | 37 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[181] | |
| Half Maximal Inhibitory Concentration (IC50) | 37 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[226] | |
| Half Maximal Inhibitory Concentration (IC50) | 37.88 | nM |
SW1990 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37.91 | nM |
MKN-1 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 370 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[163] | |
| Half Maximal Inhibitory Concentration (IC50) | 370 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[284] | |
| Half Maximal Inhibitory Concentration (IC50) | 37050 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[239] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 372.39 | nM |
LXFL 529 cells
|
Non-small cell lung carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 375 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[170] | |
| Half Maximal Inhibitory Concentration (IC50) | 3750 | nM |
SW480 cells
|
Colon adenocarcinoma
|
[285] | |
| Half Maximal Inhibitory Concentration (IC50) | 38 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 38.07 | nM |
NCI-H1648 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 38.13 | nM |
OCUB-M cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 38.4 | nM |
MMAC-SF cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 38.51 | nM |
SK-MEL-24 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 38.68 | nM |
NCI-H28 cells
|
Pleural mesothelioma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 38.82 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 380 | nM |
DU145 cells
|
Prostate carcinoma
|
[281] | |
| Half Maximal Inhibitory Concentration (IC50) | 3800 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[83] | |
| Half Maximal Inhibitory Concentration (IC50) | 3820 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[105] | |
| Half Maximal Inhibitory Concentration (IC50) | 383.65 | nM |
UACC-893 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 389.64 | nM |
RH-18 cells
|
Alveolar rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[286] | |
| Half Maximal Inhibitory Concentration (IC50) | 39.04 | nM |
TCCSUP cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39.51 | nM |
MEG-01 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39.54 | nM |
D-247MG cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 390 | nM |
DU145 cells
|
Prostate carcinoma
|
[265] | |
| Half Maximal Inhibitory Concentration (IC50) | 3910 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[100] | |
| Half Maximal Inhibitory Concentration (IC50) | 3960 | nM |
CAKI-2 cells
|
Renal carcinoma
|
[164] | |
| Half Maximal Inhibitory Concentration (IC50) | 3970 | nM |
HCT 116 cells
|
Colon carcinoma
|
[107] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[159] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[127] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[20] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
[93] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
[94] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
[97] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
MT4 cells
|
Normal
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
MT4 cells
|
Normal
|
[169] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
P388 cells
|
Lymphoma
|
[93] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
P388 cells
|
Lymphoma
|
[94] | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
P388 cells
|
Lymphoma
|
[97] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.032 | nM |
DoTc2-4510 cells
|
Cervix uteri
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.033 | nM |
EW-24 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.062 | nM |
SW982 cells
|
Biphasic synovial sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.066 | nM |
Kasumi-1 cells
|
Myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.073 | nM |
HGC-27 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.08 | nM |
EM-2 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.082 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.095 | nM |
M059J cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.17 | nM |
TE-8 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.183 | nM |
5637 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.211 | nM |
SW756 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.23 | nM |
RKO cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.251 | nM |
A-427 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.393 | nM |
KOSC-2 cells
|
Floor of mouth squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.408 | nM |
AM-38 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.503 | nM |
SN12C cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.525 | nM |
A204 cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.564 | nM |
BE-13 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.567 | nM |
FTC-133 cells
|
Thyroid gland follicular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.582 | nM |
SKG-IIIa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.662 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.677 | nM |
GB-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.713 | nM |
SK-LU-1 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.722 | nM |
J82 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.753 | nM |
RPMI-7951 cells
|
Malignant melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.758 | nM |
CAL-54 cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.94 | nM |
TYK-nu cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.97 | nM |
Ca-Ski cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[42] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[43] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[44] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[45] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[46] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[48] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[49] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 40 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | <40 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[287] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[182] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[288] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[289] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[290] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[291] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
HCT 116 cells
|
Colon carcinoma
|
[123] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[104] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
SF268 cells
|
Astrocytoma
|
[287] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[152] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
Panel (56 tumour cells)
|
Tumour
|
Undisclosed | [292] |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
BGC-823 cells
|
Stomach adenocarcinoma
|
[26] | |
| Half Maximal Inhibitory Concentration (IC50) | 40.12 | nM |
NCI-H1792 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.69 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.86 | nM |
DBTRG-05MG cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.93 | nM |
COR-L88 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 400 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
PC-3 cells
|
Prostate carcinoma
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[293] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[225] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[78] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[176] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[177] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[112] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
DU145 cells
|
Prostate carcinoma
|
[78] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
DU145 cells
|
Prostate carcinoma
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
DU145 cells
|
Prostate carcinoma
|
[268] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
HCT 116 cells
|
Colon carcinoma
|
[225] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
MIA PaCa-2 cells (MSLN expression)
|
Pancreatic ductal adenocarcinoma
|
[294] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
L2987 cells
|
Lung adenocarcinoma
|
[295] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
BEL-7404 tumor cells
|
Endocervical adenocarcinoma
|
[223] | |
| Half Maximal Inhibitory Concentration (IC50) | 4000 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[131] | |
| Half Maximal Inhibitory Concentration (IC50) | >40000 | nM |
PC-3 cells
|
Prostate carcinoma
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | >40000 | nM |
BJ cells
|
Normal
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | >40000 | nM |
TERT-RPE1 cells
|
Normal
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 4010 | nM |
DU145 cells
|
Prostate carcinoma
|
[99] | |
| Half Maximal Inhibitory Concentration (IC50) | 41 | nM |
SK-VLB cells
|
Ovarian carcinoma
|
Undisclosed | [226] |
| Half Maximal Inhibitory Concentration (IC50) | 41.48 | nM |
C8166 cells
|
Leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 410 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[268] | |
| Half Maximal Inhibitory Concentration (IC50) | 4100 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[296] | |
| Half Maximal Inhibitory Concentration (IC50) | 411.5 | nM |
KLE cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4155.69 | nM |
HCC1419 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4160 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[88] | |
| Half Maximal Inhibitory Concentration (IC50) | 42.71 | nM |
SNU-5 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 420 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[186] | |
| Half Maximal Inhibitory Concentration (IC50) | 420 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[265] | |
| Half Maximal Inhibitory Concentration (IC50) | 420 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 420 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[108] | |
| Half Maximal Inhibitory Concentration (IC50) | 4200 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[116] | |
| Half Maximal Inhibitory Concentration (IC50) | 4270 | nM |
MGC-803 cells
|
Gastric cancer
|
[233] | |
| Half Maximal Inhibitory Concentration (IC50) | 43.18 | nM |
NCI-H1092 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43.33 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43.6 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[114] | |
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM |
IMR-90 cells
|
Normal
|
[218] | |
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM |
CT26.WT cells
|
Colon adenocarcinoma
|
[156] | |
| Half Maximal Inhibitory Concentration (IC50) | 4356.62 | nM |
NY cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 436.37 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 436.47 | nM |
DJM-1 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4370 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[221] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 44 | nM |
Tumor cells
|
Tumour
|
Undisclosed | [170] |
| Half Maximal Inhibitory Concentration (IC50) | 44 | nM |
HCC70 cells
|
Breast ductal carcinoma
|
[241] | |
| Half Maximal Inhibitory Concentration (IC50) | 44.02 | nM |
NB12 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 44.69 | nM |
NCI-H720 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 44.87 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 44.89 | nM |
PANC-08-13 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4430 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[258] | |
| Half Maximal Inhibitory Concentration (IC50) | 4470 | nM |
RD cells
|
Rhabdomyosarcoma
|
[239] | |
| Half Maximal Inhibitory Concentration (IC50) | 4490 | nM |
RD cells
|
Rhabdomyosarcoma
|
[153] | |
| Half Maximal Inhibitory Concentration (IC50) | 45 | nM |
Col2 cells
|
Colon carcinoma
|
[194] | |
| Half Maximal Inhibitory Concentration (IC50) | 45 | nM |
Col2 cells
|
Colon carcinoma
|
[196] | |
| Half Maximal Inhibitory Concentration (IC50) | 45.46 | nM |
HCC70 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 450 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
[257] | |
| Half Maximal Inhibitory Concentration (IC50) | 452.29 | nM |
Capan-2 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4540 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[281] | |
| Half Maximal Inhibitory Concentration (IC50) | 455 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 459.3 | nM |
Fibroblast cells
|
Normal
|
Undisclosed | [34] |
| Half Maximal Inhibitory Concentration (IC50) | 46 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[226] | |
| Half Maximal Inhibitory Concentration (IC50) | 46.97 | nM |
MeWo cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 460 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[147] | |
| Half Maximal Inhibitory Concentration (IC50) | 460 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[138] | |
| Half Maximal Inhibitory Concentration (IC50) | 460 | nM |
SK-MEL-24 cells
|
Melanoma
|
[234] | |
| Half Maximal Inhibitory Concentration (IC50) | 46000000 | nM |
KATO III cells
|
Down syndrome
|
[166] | |
| Half Maximal Inhibitory Concentration (IC50) | 4602.33 | nM |
T84 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 47 | nM |
SK-MEL cells
|
Melanoma
|
Undisclosed | [148] |
| Half Maximal Inhibitory Concentration (IC50) | 47.35 | nM |
VMRC-RCZ cells
|
Renal cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 47.97 | nM |
M19-MEL cells
|
Melanoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 470 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[236] | |
| Half Maximal Inhibitory Concentration (IC50) | 474 | nM |
ID8 cells
|
Normal
|
[192] | |
| Half Maximal Inhibitory Concentration (IC50) | 4750 | nM |
HCT 116 cells
|
Colon carcinoma
|
[285] | |
| Half Maximal Inhibitory Concentration (IC50) | 4790 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[258] | |
| Half Maximal Inhibitory Concentration (IC50) | 4791.52 | nM |
COLO-679 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 48 | nM |
LOX IMVI cells
|
Melanoma
|
[226] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 48.31 | nM |
XF498 cells
|
Glioma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 48.53 | nM |
NCI-H2030 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 48.92 | nM |
SW837 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 480 | nM |
PC-3 cells
|
Prostate carcinoma
|
[148] | |
| Half Maximal Inhibitory Concentration (IC50) | 480 | nM |
PC-3M cells
|
Bone metastasis of prostate carcinoma
|
[210] | |
| Half Maximal Inhibitory Concentration (IC50) | 486.07 | nM |
HDLM-2 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 49 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 49 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[241] | |
| Half Maximal Inhibitory Concentration (IC50) | 490 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[145] | |
| Half Maximal Inhibitory Concentration (IC50) | 490 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[163] | |
| Half Maximal Inhibitory Concentration (IC50) | 491.21 | nM |
NCI-H2029 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4920 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[83] | |
| Half Maximal Inhibitory Concentration (IC50) | 4950 | nM |
VACO 241 cells
|
Colon carcinoma
|
[285] | |
| Half Maximal Inhibitory Concentration (IC50) | 4960 | nM |
184B5 cells
|
Normal
|
[168] | |
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[297] | |
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[72] | |
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
[298] | |
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
[95] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.021 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.023 | nM |
GCT cells
|
Pleomorphic sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.051 | nM |
HCT 116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.074 | nM |
NCI-H2087 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.083 | nM |
MN-60 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.205 | nM |
D-336MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.223 | nM |
KYSE-270 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.31 | nM |
BHY cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.354 | nM |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.377 | nM |
SK-N-AS cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.379 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[299] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 5.4 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[215] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.4 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
[300] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.453 | nM |
YKG-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.469 | nM |
HCE-T cells
|
Nornal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.5 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.5 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.5 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.5 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[29] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.5 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.547 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.6 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[142] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.6 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[143] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.6 | nM |
HEK293 cells
|
Normal
|
[30] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 5.7 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 5.753 | nM |
HLE cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.997 | nM |
CAL-33 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 50 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[216] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 50 | nM |
HCT 116 cells
|
Colon carcinoma
|
[40] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 50 | nM |
HCT 116 cells
|
Colon carcinoma
|
[228] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 50 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[62] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 50 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[63] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[290] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
DU145 cells
|
Prostate carcinoma
|
[241] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
[128] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
HCT 116 cells
|
Colon carcinoma
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[154] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[155] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[266] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[267] | |
| Half Maximal Inhibitory Concentration (IC50) | 50.3 | nM |
NCI-H810 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[150] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[301] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[293] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[241] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[78] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
[173] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
CRL-7065 cells
|
Normal
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[186] | |
| Half Maximal Inhibitory Concentration (IC50) | 50880 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[235] | |
| Half Maximal Inhibitory Concentration (IC50) | 51 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[302] | |
| Half Maximal Inhibitory Concentration (IC50) | 51.21 | nM |
MKN-28 cells
|
Gastric epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 51.29 | nM |
SK-MEL-1 cells
|
Metastatic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 51.69 | nM |
SW1463 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 510 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[192] | |
| Half Maximal Inhibitory Concentration (IC50) | 51500 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[235] | |
| Half Maximal Inhibitory Concentration (IC50) | 517.64 | nM |
LN-405 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52 | nM |
PC-3 cells
|
Prostate carcinoma
|
[198] | |
| Half Maximal Inhibitory Concentration (IC50) | 52 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 52.7 | nM |
SW1417 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 520 | nM |
CA46 cells
|
Burkitt lymphoma
|
[165] | |
| Half Maximal Inhibitory Concentration (IC50) | 520 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[268] | |
| Half Maximal Inhibitory Concentration (IC50) | 5270.72 | nM |
MFM-223 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53 | nM |
SK-VLB cells
|
Ovarian carcinoma
|
Undisclosed | [302] |
| Half Maximal Inhibitory Concentration (IC50) | 53.71 | nM |
TGBC24TKB cells
|
Gallbladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5300 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[303] | |
| Half Maximal Inhibitory Concentration (IC50) | 5370 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[120] | |
| Half Maximal Inhibitory Concentration (IC50) | 5370 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[233] | |
| Half Maximal Inhibitory Concentration (IC50) | 5380 | nM |
NHDF cells
|
Normal
|
Undisclosed | [188] |
| Half Maximal Inhibitory Concentration (IC50) | 5385 | nM |
CEM/C2 cells
|
T acute lymphoblastic leukemia
|
[25] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 54.33 | nM |
UACC-257 cells
|
Melanoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 54.75 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 54.96 | nM |
NCI-H650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 540 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[115] | |
| Half Maximal Inhibitory Concentration (IC50) | 540 | nM |
H22 cells
|
Hepatoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 54690 | nM |
HEK293 cells
|
Normal
|
[153] | |
| Half Maximal Inhibitory Concentration (IC50) | 55.12 | nM |
HPAF-II cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 55.5 | nM |
HCC2218 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 55.67 | nM |
KM-H2 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 55.79 | nM |
TK-10 cells
|
Renal carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 550 | nM |
SiHa cells
|
Cervical squamous cell carcinoma
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 5500 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[82] | |
| Half Maximal Inhibitory Concentration (IC50) | 5500 | nM |
M059J cells
|
Glioblastoma
|
[213] | |
| Half Maximal Inhibitory Concentration (IC50) | 5500 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[85] | |
| Half Maximal Inhibitory Concentration (IC50) | 56 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[304] | |
| Half Maximal Inhibitory Concentration (IC50) | 56.63 | nM |
NCI-H446 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 56.73 | nM |
SCC-25 cells
|
Squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 56.87 | nM |
C3A cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 560 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 5650 | nM |
HEK-293T cells
|
Normal
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 5690 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[233] | |
| Half Maximal Inhibitory Concentration (IC50) | 57 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[269] | |
| Half Maximal Inhibitory Concentration (IC50) | 57 | nM |
PC-3 cells
|
Prostate carcinoma
|
[243] | |
| Half Maximal Inhibitory Concentration (IC50) | 57 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[243] | |
| Half Maximal Inhibitory Concentration (IC50) | 57 | nM |
MES-SA cells
|
Uterine sarcoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 57 | nM |
BGC-823 cells
|
Stomach adenocarcinoma
|
[161] | |
| Half Maximal Inhibitory Concentration (IC50) | 57.87 | nM |
KS-1 cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 570 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[208] | |
| Half Maximal Inhibitory Concentration (IC50) | 5770 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[168] | |
| Half Maximal Inhibitory Concentration (IC50) | 58 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[305] | |
| Half Maximal Inhibitory Concentration (IC50) | 58.08 | nM |
LS-411N cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58.48 | nM |
NCI-H2405 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 580 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 5800 | nM |
SGC-7901 cells
|
Gastric carcinoma
|
[156] | |
| Half Maximal Inhibitory Concentration (IC50) | 588.29 | nM |
NCI-H82 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 59.28 | nM |
NCI-H1304 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 59.8 | nM |
SH-4 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 590 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[306] | |
| Half Maximal Inhibitory Concentration (IC50) | 590 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[245] | |
| Half Maximal Inhibitory Concentration (IC50) | 590 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[118] | |
| Half Maximal Inhibitory Concentration (IC50) | 590 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[281] | |
| Half Maximal Inhibitory Concentration (IC50) | 59130 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[98] | |
| Half Maximal Inhibitory Concentration (IC50) | 5930 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[134] | |
| Half Maximal Inhibitory Concentration (IC50) | 5930 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[135] | |
| Half Maximal Inhibitory Concentration (IC50) | 594.73 | nM |
CAL-120 cells
|
Breast carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 6 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[207] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
DC3F cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[161] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
[162] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
T24 cells
|
Bladder carcinoma
|
[158] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
[96] | |
| Half Maximal Inhibitory Concentration (IC50) | 6.072 | nM |
DMS-273 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.091 | nM |
CHL-1 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.3 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[300] | |
| Half Maximal Inhibitory Concentration (IC50) | 6.311 | nM |
HEL cells
|
Erythroleukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.427 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.427 | nM |
CaR-1 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.477 | nM |
C-33-A cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.515 | nM |
NCI-H1703 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.632 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.663 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.7 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[307] | |
| Half Maximal Inhibitory Concentration (IC50) | 6.754 | nM |
KYSE-510 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.849 | nM |
COR-L23 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.925 | nM |
BFTC-909 cells
|
Renal pelvis urothelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.965 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 60 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[40] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 60 | nM |
PC-3 cells
|
Prostate carcinoma
|
[62] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 60 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[208] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 60 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[62] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 60 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[128] | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[232] | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[290] | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[308] | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
HEC-1B cells
|
Endometrial adenocarcinoma
|
[166] | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
[273] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 600 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[309] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 600 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[204] | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[211] | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[293] | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT 116 cells
|
Colon carcinoma
|
[163] | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[231] | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HEK293 cells
|
Normal
|
[225] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 6000 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[148] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 6000 | nM |
SAS cells
|
Tongue squamous cell carcinoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 6000 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[213] | |
| Half Maximal Inhibitory Concentration (IC50) | 6000 | nM |
SAS cells
|
Tongue squamous cell carcinoma
|
[171] | |
| Half Maximal Inhibitory Concentration (IC50) | 60010 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[244] | |
| Half Maximal Inhibitory Concentration (IC50) | 6080 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[108] | |
| Half Maximal Inhibitory Concentration (IC50) | 6080 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[180] | |
| Half Maximal Inhibitory Concentration (IC50) | 61.7 | nM |
RKO cells
|
Colon carcinoma
|
[156] | |
| Half Maximal Inhibitory Concentration (IC50) | 610 | nM |
DU145 cells
|
Prostate carcinoma
|
[245] | |
| Half Maximal Inhibitory Concentration (IC50) | 610 | nM |
SH-SY5Y cells
|
Bone marrow neuroblastoma
|
[163] | |
| Half Maximal Inhibitory Concentration (IC50) | 61000 | nM |
CPT-K5 cells
|
T acute lymphoblastic leukemia
|
[95] | |
| Half Maximal Inhibitory Concentration (IC50) | 6130 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[168] | |
| Half Maximal Inhibitory Concentration (IC50) | 618.33 | nM |
NCI-H2342 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 62.09 | nM |
COLO 320HSR cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 620 | nM |
Macrophage cells
|
Normal
|
Undisclosed | [310] |
| Half Maximal Inhibitory Concentration (IC50) | 628.09 | nM |
SCH cells
|
Gastric choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 630 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[308] | |
| Half Maximal Inhibitory Concentration (IC50) | 6300 | nM |
Bel-7402 cells
|
Hepatoma
|
[26] | |
| Half Maximal Inhibitory Concentration (IC50) | <64 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[257] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 64.42 | nM |
PC-3 cells
|
Prostate carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 640 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[311] | |
| Half Maximal Inhibitory Concentration (IC50) | 6400 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[175] | |
| Half Maximal Inhibitory Concentration (IC50) | >6400 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 65 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[282] | |
| Half Maximal Inhibitory Concentration (IC50) | 65 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[107] | |
| Half Maximal Inhibitory Concentration (IC50) | 65.1 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[192] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 65.77 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 650 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[312] | |
| Half Maximal Inhibitory Concentration (IC50) | 650 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[173] | |
| Half Maximal Inhibitory Concentration (IC50) | 6510 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[258] | |
| Half Maximal Inhibitory Concentration (IC50) | 66 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[164] | |
| Half Maximal Inhibitory Concentration (IC50) | 66.1 | nM |
NCI-H1355 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 66.15 | nM |
GCIY cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 660 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[313] | |
| Half Maximal Inhibitory Concentration (IC50) | 660 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[108] | |
| Half Maximal Inhibitory Concentration (IC50) | 660 | nM |
DU145 cells
|
Prostate carcinoma
|
[308] | |
| Half Maximal Inhibitory Concentration (IC50) | 660 | nM |
A375 cells
|
Amelanotic melanoma
|
[163] | |
| Half Maximal Inhibitory Concentration (IC50) | 67 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 67 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[222] | |
| Half Maximal Inhibitory Concentration (IC50) | 6700 | nM |
HCT 116 cells
|
Colon carcinoma
|
[134] | |
| Half Maximal Inhibitory Concentration (IC50) | 68.13 | nM |
NCI-H2009 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 680 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[314] | |
| Half Maximal Inhibitory Concentration (IC50) | 680 | nM |
U-937 cells
|
Adult acute monocytic leukemia
|
[270] | |
| Half Maximal Inhibitory Concentration (IC50) | 680 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[87] | |
| Half Maximal Inhibitory Concentration (IC50) | 680 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[313] | |
| Half Maximal Inhibitory Concentration (IC50) | 680 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[257] | |
| Half Maximal Inhibitory Concentration (IC50) | 6800 | nM |
T24 cells
|
Bladder carcinoma
|
[258] | |
| Half Maximal Inhibitory Concentration (IC50) | 69 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[194] | |
| Half Maximal Inhibitory Concentration (IC50) | 69 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[196] | |
| Half Maximal Inhibitory Concentration (IC50) | 69.51 | nM |
U266B1 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 69.74 | nM |
KYSE-140 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 69.89 | nM |
KALS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 690 | nM |
HEK-293T cells
|
Normal
|
[163] | |
| Half Maximal Inhibitory Concentration (IC50) | 6960 | nM |
PC-3 cells
|
Prostate carcinoma
|
[315] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 7 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[216] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 7 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[227] | |
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[72] | |
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[316] | |
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
Bel-7402 cells
|
Hepatoma
|
[316] | |
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
P388 cells
|
Lymphoma
|
[317] | |
| Half Maximal Inhibitory Concentration (IC50) | 7.02 | nM |
LAMA-84 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.054 | nM |
LXF-289 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.077 | nM |
A498 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.079 | nM |
ESS-1 cells
|
Endometrioid stromal sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.103 | nM |
Panc 03.27 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.253 | nM |
SK-HEP1 cells
|
Hepatoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.263 | nM |
OAW-28 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.272 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.311 | nM |
GMS-10 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.38 | nM |
TE-5 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.569 | nM |
MDA-MB-157 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.628 | nM |
MEL-HO cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.654 | nM |
MG-63 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.701 | nM |
KNS-62 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.8 | nM |
NCI-H928 cells
|
Normal
|
Undisclosed | [300] |
| Half Maximal Inhibitory Concentration (IC50) | 7.897 | nM |
LB1047-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.904 | nM |
EC-GI-10 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.909 | nM |
SF-295 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[120] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[284] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
DU145 cells
|
Prostate carcinoma
|
[318] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
BT-20 cells
|
Invasive breast carcinoma of no special type
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
BT-20 cells
|
Invasive breast carcinoma of no special type
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
HCT 116 cells
|
Colon carcinoma
|
[312] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[104] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[256] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[154] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[155] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
CAMA-1 cells
|
Breast adenocarcinoma
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
CAMA-1 cells
|
Breast adenocarcinoma
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
[209] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
SF268 cells
|
Astrocytoma
|
[218] | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[287] | |
| Half Maximal Inhibitory Concentration (IC50) | 700 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[130] | |
| Half Maximal Inhibitory Concentration (IC50) | 700 | nM |
HEp-2 cells
|
Laryngeal carcinoma
|
[222] | |
| Half Maximal Inhibitory Concentration (IC50) | 7000 | nM |
BT474-M1 cells
|
Invasive breast carcinoma
|
[296] | |
| Half Maximal Inhibitory Concentration (IC50) | 71 | nM |
THP-1 cells
|
Childhood acute monocytic leukemia
|
[211] | |
| Half Maximal Inhibitory Concentration (IC50) | 71.47 | nM |
RVH-421 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 710 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[269] | |
| Half Maximal Inhibitory Concentration (IC50) | 710 | nM |
SW579 cells
|
Thyroid carcinoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 7100 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[296] | |
| Half Maximal Inhibitory Concentration (IC50) | 711 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 711.49 | nM |
SW684 cells
|
Fibrosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 71300 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[244] | |
| Half Maximal Inhibitory Concentration (IC50) | 72 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[305] | |
| Half Maximal Inhibitory Concentration (IC50) | 72.08 | nM |
CP50-MEL-B cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 72.45 | nM |
COLO-680N cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 72.8 | nM |
EPLC-272H cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7210.91 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7325.59 | nM |
LS-123 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 736.29 | nM |
KP-N-YS cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 74 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[123] | |
| Half Maximal Inhibitory Concentration (IC50) | 74.99 | nM |
KM12 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7420 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[167] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 75 | nM |
HCT 116 cells
|
Colon carcinoma
|
[207] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 75 | nM |
HCT 116 cells
|
Colon carcinoma
|
[227] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 75 | nM |
HCT 116 cells
|
Colon carcinoma
|
[122] | |
| Half Maximal Inhibitory Concentration (IC50) | 750 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[212] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 76.38 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 76.9 | nM |
SW626 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 760 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[308] | |
| Half Maximal Inhibitory Concentration (IC50) | 760 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[240] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 77.62 | nM |
KM-20L2 cells
|
Colon carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 776.97 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78 | nM |
PC-3 cells
|
Prostate carcinoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 78.11 | nM |
KYSE-410 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78.21 | nM |
OMC-1 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 780 | nM |
HEK293 cells
|
Normal
|
[265] | |
| Half Maximal Inhibitory Concentration (IC50) | 786 | nM |
WI-38 cells
|
Normal
|
[192] | |
| Half Maximal Inhibitory Concentration (IC50) | 7860 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
[187] | |
| Half Maximal Inhibitory Concentration (IC50) | 7923.68 | nM |
CAL-85-1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7940 | nM |
HEK293 cells
|
Normal
|
[319] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 8 | nM |
LoVo cells
|
Colon adenocarcinoma
|
[148] | |
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[316] | |
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[211] | |
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[302] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.123 | nM |
KY821 cells
|
Acute myelomonocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.136 | nM |
LCLC-97TM1 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.238 | nM |
MSTO-211H cells
|
Pleural biphasic mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.365 | nM |
KU812 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.5 | nM |
HCT 116 cells
|
Colon carcinoma
|
[253] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.612 | nM |
MZ7-mel cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.63 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[266] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.63 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[267] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.743 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.787 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.8 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[320] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.887 | nM |
HMV-2 cells
|
Vaginal melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.99 | nM |
OAW-42 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 80 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[311] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[308] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[263] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[90] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[229] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
HT-1080 cells (FAP expression)
|
Fibrosarcoma
|
[194] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
HT-1080 cells (FAP expression)
|
Fibrosarcoma
|
[195] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
HT-1080 cells (FAP expression)
|
Fibrosarcoma
|
[196] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[113] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[218] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[112] | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
IMR-32 cells
|
Neuroblastoma
|
[222] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 80.91 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 80.99 | nM |
EFO-27 cells
|
Ovarian mucinous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[321] | |
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
DU145 cells
|
Prostate carcinoma
|
[293] | |
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[245] | |
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
NCI-H1299 cells (MMAE resistant)
|
Lung large cell carcinoma
|
[130] | |
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
MRC5 cells
|
Normal
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 81.1 | nM |
DMS 114 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 816.58 | nM |
Hs 578T cells
|
Invasive breast carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 82.56 | nM |
KYSE-520 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8280 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[92] | |
| Half Maximal Inhibitory Concentration (IC50) | 83 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[159] | |
| Half Maximal Inhibitory Concentration (IC50) | 83.02 | nM |
MDA-MB-175-VII cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 830 | nM |
HEK293 cells
|
Normal
|
[106] | |
| Half Maximal Inhibitory Concentration (IC50) | 8370 | nM |
WI-38 cells
|
Normal
|
[258] | |
| Half Maximal Inhibitory Concentration (IC50) | 84 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[286] | |
| Half Maximal Inhibitory Concentration (IC50) | 84.75 | nM |
DK-MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 85 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[322] | |
| Half Maximal Inhibitory Concentration (IC50) | 85.52 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 85.66 | nM |
ACN cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 850 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[282] | |
| Half Maximal Inhibitory Concentration (IC50) | 86.1 | nM |
LNCaP cells
|
Prostate carcinoma
|
[254] | |
| Half Maximal Inhibitory Concentration (IC50) | 86.88 | nM |
SiHa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 860 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[282] | |
| Half Maximal Inhibitory Concentration (IC50) | 8640 | nM |
HEC-1B cells
|
Endometrial adenocarcinoma
|
[164] | |
| Half Maximal Inhibitory Concentration (IC50) | 87.25 | nM |
LB2518-MEL cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 87.43 | nM |
CAMA-1 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 87.5 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[266] | |
| Half Maximal Inhibitory Concentration (IC50) | 87.8 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[302] | |
| Half Maximal Inhibitory Concentration (IC50) | 8750 | nM |
HEK293 cells
|
Normal
|
[248] | |
| Half Maximal Inhibitory Concentration (IC50) | 88 | nM |
T24 cells
|
Bladder carcinoma
|
[323] | |
| Half Maximal Inhibitory Concentration (IC50) | 88.05 | nM |
ES6 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8830 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[193] | |
| Half Maximal Inhibitory Concentration (IC50) | 8870 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[153] | |
| Half Maximal Inhibitory Concentration (IC50) | 89 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[305] | |
| Half Maximal Inhibitory Concentration (IC50) | 890 | nM |
HEK293 cells
|
Normal
|
[134] | |
| Half Maximal Inhibitory Concentration (IC50) | 890 | nM |
MRC5 cells
|
Normal
|
[117] | |
| Half Maximal Inhibitory Concentration (IC50) | 8900 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[92] | |
| Half Maximal Inhibitory Concentration (IC50) | 8930 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[324] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 9 | nM |
HCT 116 cells
|
Colon carcinoma
|
[207] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 9 | nM |
HCT 116 cells
|
Colon carcinoma
|
[227] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 9 | nM |
HCT 116 cells
|
Colon carcinoma
|
[122] | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[141] | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
HCT 116 cells
|
Colon carcinoma
|
[127] | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
P388 cells
|
Lymphoma
|
[95] | |
| Half Maximal Inhibitory Concentration (IC50) | 9.009 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.114 | nM |
D-263MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.314 | nM |
22RV1 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.425 | nM |
NCI-H1299 cells (MMAE resistant)
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.753 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.948 | nM |
M14 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.968 | nM |
OS-RC-2 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 90 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[148] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 90 | nM |
PC-3 cells
|
Prostate carcinoma
|
[199] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 90 | nM |
PC-3 cells
|
Prostate carcinoma
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[257] | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
PANC-1 cells
|
Pancreatic ductal adenocarcinoma
|
[200] | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[221] | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[231] | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
HCT 116 cells
|
Colon carcinoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
HCT 116 cells
|
Colon carcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[229] | |
| Half Maximal Inhibitory Concentration (IC50) | 90.89 | nM |
NCI-H2452 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 900 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[26] | |
| Half Maximal Inhibitory Concentration (IC50) | 900 | nM |
SK-HEP1 cells
|
Hepatoma
|
[223] | |
| Half Maximal Inhibitory Concentration (IC50) | 91 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[187] | |
| Half Maximal Inhibitory Concentration (IC50) | 91.19 | nM |
LB373-MEL-D cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 91.86 | nM |
NOS-1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9170 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[319] | |
| Half Maximal Inhibitory Concentration (IC50) | 92.14 | nM |
KYSE-70 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 920 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[315] | |
| Half Maximal Inhibitory Concentration (IC50) | 920 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[282] | |
| Half Maximal Inhibitory Concentration (IC50) | 9290 | nM |
DU145 cells
|
Prostate carcinoma
|
[319] | |
| Half Maximal Inhibitory Concentration (IC50) | 93.98 | nM |
8305C cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 937.56 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 940 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[306] | |
| Half Maximal Inhibitory Concentration (IC50) | 940 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[206] | |
| Half Maximal Inhibitory Concentration (IC50) | 940 | nM |
DU145 cells
|
Prostate carcinoma
|
[311] | |
| Half Maximal Inhibitory Concentration (IC50) | 9450 | nM |
MGC-803 cells
|
Gastric cancer
|
[102] | |
| Half Maximal Inhibitory Concentration (IC50) | 9492.4 | nM |
LS1034 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 95.06 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 95.58 | nM |
H-EMC-SS cells
|
Extraskeletal myxoid chondrosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 950 | nM |
DU145 cells
|
Prostate carcinoma
|
[212] | |
| Half Maximal Inhibitory Concentration (IC50) | 9520 | nM |
Eca-109 cells
|
Esophageal squamous cell carcinoma
|
[119] | |
| Half Maximal Inhibitory Concentration (IC50) | 9550 | nM |
Caco-2 cells
|
Colon adenocarcinoma
|
[89] | |
| Half Maximal Inhibitory Concentration (IC50) | 956.65 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 960 | nM |
SK-HEP1 cells
|
Hepatoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 9621.56 | nM |
NCI-H1993 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9670 | nM |
BGC-823 cells
|
Stomach adenocarcinoma
|
[136] | |
| Half Maximal Inhibitory Concentration (IC50) | 970 | nM |
Farage cells
|
Normal
|
[325] | |
| Half Maximal Inhibitory Concentration (IC50) | 970 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[107] | |
| Half Maximal Inhibitory Concentration (IC50) | 970 | nM |
MCF-10A cells
|
Normal
|
[113] | |
| Half Maximal Inhibitory Concentration (IC50) | 9700 | nM |
BGC-823 cells
|
Stomach adenocarcinoma
|
[137] | |
| Half Maximal Inhibitory Concentration (IC50) | 975.25 | nM |
NCI-H2291 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 98 | nM |
SNU-638 cells
|
Gastric carcinoma
|
[194] | |
| Half Maximal Inhibitory Concentration (IC50) | 98 | nM |
SNU-638 cells
|
Gastric carcinoma
|
[195] | |
| Half Maximal Inhibitory Concentration (IC50) | 98 | nM |
SNU-638 cells
|
Gastric carcinoma
|
[196] | |
| Half Maximal Inhibitory Concentration (IC50) | 980 | nM |
CNE-2 cells
|
Normal
|
[108] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 99 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[122] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 99 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[227] | |
| Half Maximal Inhibitory Concentration (IC50) | 99 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[19] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 990 | nM |
Detroit 551 cells
|
Normal
|
[208] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 990 | nM |
Detroit 551 cells
|
Normal
|
[103] | |
| Half Maximal Inhibitory Concentration (IC50) | 990 | nM |
Detroit 551 cells
|
Normal
|
[171] | |
| Half Maximal Inhibitory Concentration (IC50) | 9920 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[319] |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
WO2024105206A1 2i-5657 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
13Nj.9 nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 2 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
103ᇷ nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1003뎯 nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1003뎯 nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 5 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
1.0- 9.9 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 7 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells (+NE) | CVCL_1051 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
1.0- 9.9 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 6 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI-H929 cells (+NE) | CVCL_1600 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
1.0- 9.9 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 6 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Breast inflammatory carcinoma | SUM149PT cells (+NE) | CVCL_3422 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 7 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells (-NE) | CVCL_1051 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 6 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI-H929 cells (-NE) | CVCL_1600 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 6 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Breast inflammatory carcinoma | SUM149PT cells (-NE) | CVCL_3422 | ||
WO2024105206A1 2k-2658 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
103ᇷ nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
103ᇷ nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 3 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
103ᇷ nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 4 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1003뎯 nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 8 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells (-NE) | CVCL_1051 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 8 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells (+NE) | CVCL_1051 | ||
WO2024105206A1 40p-Avelu 2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
0.01- 1 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 38 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells (+NE) | CVCL_1051 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
0.01- 1 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 36 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI-H929 cells (+NE) | CVCL_1600 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
0.01- 1 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 36 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Breast inflammatory carcinoma | SUM149PT cells (+NE) | CVCL_3422 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
1.0- 9.9 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 41 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | HT29 cells (+NE) | CVCL_0320 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 38 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells (-NE) | CVCL_1051 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 21 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | HT29 cells (-NE) | CVCL_0320 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 36 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI-H929 cells (-NE) | CVCL_1600 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 36 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Breast inflammatory carcinoma | SUM149PT cells (-NE) | CVCL_3422 | ||
WO2024105206A1 36p-Avelu 2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
1.0- 9.9 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 32 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Breast inflammatory carcinoma | SUM149PT cells (+NE) | CVCL_3422 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 34 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells (-NE) | CVCL_1051 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 34 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells (+NE) | CVCL_1051 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 17 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | HT29 cells (-NE) | CVCL_0320 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 37 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Colon adenocarcinoma | HT29 cells (+NE) | CVCL_0320 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 32 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI-H929 cells (-NE) | CVCL_1600 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 32 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI-H929 cells (+NE) | CVCL_1600 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [326] | ||||
| Efficacy Data | Activity Concentration at -50% (AC50) |
10- 99 nM
|
|||
| Method Description |
After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 32 % carbon dioxide.
Click to Show/Hide
|
||||
| In Vitro Model | Breast inflammatory carcinoma | SUM149PT cells (-NE) | CVCL_3422 | ||
References